Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis
Authors:
Open Access
- 9 May 2024
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (5) , 1211-1227
Abstract
Introduction A three-pronged approach to acne treatment combining an antibiotic, antimicrobial, and retinoid may be more efficacious than single/double treatments while potentially reducing antibiotic resistance. This study evaluated the efficacy and safety of the first fixed-dose, triple-combination topical acne product, clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB) using pooled phase 3 data. Methods In two identical phase 3 (N = 183; N = 180), double-blind, 12-week studies, participants aged ≥ 9 years with moderate-to-severe acne were randomized 2:1 to receive once-daily CAB or vehicle gel. Endpoints included ≥ 2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin (treatment success) and least-squares mean percent change from baseline in acne lesion counts. Treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were evaluated. Results At week 12, 50.0% of participants achieved treatment success with CAB versus 22.6% with vehicle gel (P < 0.001). CAB resulted in > 70% reductions in inflammatory and noninflammatory lesions at week 12 (77.9% and 73.0%, respectively), which were significantly greater than vehicle (57.9% and 48.2%; P < 0.001, both). Most TEAEs were of mild-moderate severity, and < 3% of CAB-treated participants discontinued study/treatment because of AEs. Transient increases from baseline in scaling, erythema, itching, burning, and stinging were observed with CAB, but resolved back to or near baseline values by week 12. Conclusions The innovative fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel was efficacious and well tolerated in children, adolescents, and adults with moderate-to-severe acne. Half of participants achieved clear/almost clear skin by 12 weeks, rates not previously seen in clinical studies of other topical acne products. Trial Registration ClinicalTrials.gov identifier NCT04214639 and NCT04214652.Keywords
This publication has 39 references indexed in Scilit:
- A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.2009
- An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patientsJournal of the American Academy of Dermatology, 2008
- The burden of skin diseases: 2004Journal of the American Academy of Dermatology, 2006
- ‘Keratolytic’ Properties of Benzoyl Peroxide and Retinoic Acid Resemble Salicylic Acid in ManSkin Pharmacology and Physiology, 2006
- Reliability of Dermatologists in Acne Lesion Counts and Global AssessmentsJournal of Cutaneous Medicine and Surgery, 2006
- Health-related quality of life among patients with facial acne − assessment of a new acne-specific questionnaireClinical and Experimental Dermatology, 2001
- A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.2001
- Comparison of the Efficacy and Safety of a Combination Topical Gel Formulation of Benzoyl Peroxide and Clindamycin with Benzoyl Peroxide, Clindamycin and Vehicle Gel in the Treatments of Acne VulgarisAmerican Journal of Clinical Dermatology, 2001
- Pharmacology and chemistry of adapaleneJournal of the American Academy of Dermatology, 1997
- Pathogenesis and Pathogenesis Related Treatment of AcneThe Journal of Dermatology, 1991